Literature DB >> 19116719

Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis.

Paola Coral-Alvarado1, Gerardo Quintana, Maria Fernanda Garces, Libia Alexandra Cepeda, Jorge Eduardo Caminos, Federico Rondon, Antonio Iglesias-Gamarra, Jose Felix Restrepo.   

Abstract

Pulmonary arterial hypertension (PAH) is the major complication of systemic sclerosis (SSc) and the main cause of morbi-mortality. It is important to find predictors for this vascular problem. The objective of this study was to determine the serum levels of different biomarkers in patients with SSc and secondary PAH and to compare them with those of healthy control subjects to define their potential role as predictors of PAH. Cross-section study in which 20 patients with SSc were included. PAH was diagnosed by echocardiogram. The optical densities of endoglin (Eng), endothelin-1 (ET-1), platelet-derived growth factor (PDGF), tumoral necrosis factor alpha (TNF-alpha), Transforming growth factor beta 2 (TGF-beta2) and Interleukin 8 (IL-8) were measured in 20 patients with SSc and 20 healthy controls matched by sex. The differences found between the group of patients with PAH and the control group were (mean or median and range): ET-1 (0.20; 0.10-0.35 vs. 0.16; 0.10-0.24; P = 0.0276), IL-8 (195.7; 45.5-504 vs. 118.9; 23-299.5; P = 0.0364), TNF-alpha (0.70; 0.50-0.96 vs. 0.48; 0.38-0.65; P = 1 x 10(-8)) and Eng (0.95; 0.57-1.72 vs. 0.75; 0.57-0.89; P = 0.0028). A correlation was found between the progression of the disease and the development of Raynaud's phenomenon (Rho: 0.67 and P = 0.0011), ET-1 and Eng (Rho: 0.53 and P = 0.0196), and between IL-8 and Eng (Rho: 0.68 and P = 0.0019). In conclusions, the elevation of the serum levels of Eng and ET-1 could represent a useful tool as PAH biomarkers. Nevertheless, the diagnostic value of these markers needs to be determined by prospective studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116719     DOI: 10.1007/s00296-008-0829-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  49 in total

Review 1.  New insights into the pathogenesis of systemic sclerosis.

Authors:  Mathieu C Tamby; Youri Chanseaud; Loïc Guillevin; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2003-05       Impact factor: 9.754

Review 2.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis.

Authors:  John Varga
Journal:  Arthritis Rheum       Date:  2002-07

3.  Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis.

Authors:  Jennifer G Walker; John Stirling; Dimitra Beroukas; Kencana Dharmapatni; David R Haynes; Malcolm D Smith; Michael J Ahern; Peter J Roberts-Thomson
Journal:  Pathology       Date:  2005-06       Impact factor: 5.306

Review 4.  The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology.

Authors:  J G Coghlan; D Mukerjee
Journal:  Curr Opin Rheumatol       Date:  2001-11       Impact factor: 5.006

5.  The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).

Authors:  Fredrick M Wigley; Joao A C Lima; Maureen Mayes; David McLain; J Lincoln Chapin; Clive Ward-Able
Journal:  Arthritis Rheum       Date:  2005-07

6.  Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts.

Authors:  A Leask; D J Abraham; D R Finlay; A Holmes; D Pennington; X Shi-Wen; Y Chen; K Venstrom; X Dou; M Ponticos; C Black; C Bernabeu; J K Jackman; P R Findell; M K Connolly
Journal:  Arthritis Rheum       Date:  2002-07

Review 7.  Pulmonary hypertension in systemic sclerosis.

Authors:  Christopher P Denton; Carol M Black
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

8.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

Authors:  P J Clements; P A Lachenbruch; J R Seibold; B Zee; V D Steen; P Brennan; A J Silman; N Allegar; J Varga; M Massa
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

9.  Plasma TGF beta in systemic sclerosis: a cross-sectional study.

Authors:  N Snowden; B Coupes; A Herrick; K Illingworth; M I Jayson; P E Brenchley
Journal:  Ann Rheum Dis       Date:  1994-11       Impact factor: 19.103

10.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  13 in total

Review 1.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

2.  Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Klio Papadopoulou; Tilemahos Sfetsios; Haralambos Karvounis; Hariklia Dimitroula; Despina Parcharidou; Georgios Koliakos; Alexandros Garyfallos; Ioannis Styliadis; Loukas Settas
Journal:  Clin Rheumatol       Date:  2010-06-05       Impact factor: 2.980

3.  Associated pulmonary arterial hypertension in connective tissue diseases.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-04

Review 4.  Role of endoglin in fibrosis and scleroderma.

Authors:  Janita A Maring; Maria Trojanowska; Peter ten Dijke
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 5.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

6.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

7.  Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure.

Authors:  Paola Ximena Coral-Alvarado; Maria Fernanda Garces; Jorge Eduardo Caminos; Antonio Iglesias-Gamarra; José Félix Restrepo; Gerardo Quintana
Journal:  Int J Rheumatol       Date:  2010-08-24

8.  Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis.

Authors:  Michał Ciurzyński; Piotr Bienias; Katarzyna Irzyk; Maciej Kostrubiec; Zbigniew Bartoszewicz; Maria Siwicka; Anna Stelmaszczyk-Emmel; Elżbieta Górska; Urszula Demkow; Piotr Pruszczyk
Journal:  Clin Rheumatol       Date:  2013-08-14       Impact factor: 2.980

9.  Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.

Authors:  Angela Kill; Christoph Tabeling; Reinmar Undeutsch; Anja A Kühl; Jeannine Günther; Mislav Radic; Mike O Becker; Harald Heidecke; Margitta Worm; Martin Witzenrath; Gerd-Rüdiger Burmester; Duska Dragun; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2014-01-28       Impact factor: 5.156

10.  Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis.

Authors:  Jérôme Avouac; Maeva Vallucci; Vanessa Smith; Patricia Senet; Barbara Ruiz; Alberto Sulli; Carmen Pizzorni; Camille Frances; Gilles Chiocchia; Maurizio Cutolo; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2013-04-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.